

REMARKS

In response to the Restriction Requirement dated February 16, 2010, Applicant hereby elects the invention of Group II (claims 3, 5, and 6) without traverse.

With respect to further restriction, Applicants elect the combination as set out in claim 3. Claim 3 recites a polynucleotide molecule which includes the combination of SNPs 10 and 17 or the combination of SNPs 26 and 29.

In view of the foregoing, applicants submit that this case is in condition for allowance and such allowance is earnestly solicited.

Respectfully submitted,

Date: March 11, 2010

/karla weyand /
Karla Weyand
Reg. No. 40,223

Siemens Healthcare Diagnostics Inc
511 Benedict Ave
Tarrytown, New York 10591
Tel: 914-524-2741